Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Follicular Lymphoma
Conditions
Keywords
Diffuse Large B-cell Lymphoma, DLBCL, Acute Lymphoblastic Leukemia, ALL, Tisagenlecleucel, Brazil, NIS, Follicular Lymphoma
Brief summary
This will be a multicenter, national, non-interventional, prospective cohort study
Detailed description
Eligible participants will be pediatric (\<18 years) and adult patients (aged 18 years or older) with B-cell malignancies who have received tisagenlecleucel through the commercial setting or out-of-specification (OOS) use in Brazil. We will collect data prospectively and complement missing information with retrospective data collection, when necessary. It is anticipated that approximately 200 patients will be enrolled in the cohort over 5 years divided among the study indications. Since this is a non-interventional study, no administration of study drug or application of questionnaires will be mandated by this protocol. The study will consist of a Pre-infusion and a Post infusion follow-up period for up to 15 years post tisagenlecleucel infusion. All patients will be followed until death or last scheduled visit, whichever comes first. For the study, pre-infusion and follow-up post infusion phases are defined as: * Pre-infusion will consist of the patient's information from the time of diagnosis untiljust prior to infusion with tisagenlecleucel. * Follow-up Post infusion information will comprise any information from the infusionof tisagenlecleucel onwards.
Interventions
OTHERtisagenlecleucel
Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study
Sponsors
Novartis Pharmaceuticals
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
0 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
Patients eligible for inclusion in this study must meet the following criteria: 1. Patients who receive tisagenlecleucel infusion in the commercial setting or out-of-specification (OOS) use, AND 2. Signed informed consent must be obtained prior to participation in study, AND For ALL participants: 3. Patients of any gender aged 0-17 years (named as pediatric) with relapsed/ refractory B-cell ALL diagnosis that received tisagenlecleucel infusion, OR 4. Patients of any gender, aged 18-25 years (named as adults) - with relapsed/ refractory B-cell ALL diagnosis that received tisagenlecleucel infusion, OR For DBLCL and FL participants: 5. Patients of any gender aged 18 years or older, who have been diagnosed with relapsed/ refractory Diffuse Large B-cell Lymphoma and received tisagenlecleucel infusion.
Exclusion criteria
1. Patients who did not consent to data collection. 2. Patients who received tisagenlecleucel infusion as part of any interventional clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of ALL patients with hematologic recovery | Up to 15 years | Dates of hematological recovery (i.e., dates of Absolute Neutrophil Count (ANC) and platelet recovery) will be collected. ANC recovery is defined as an ANC of ≥ 0.5 × 109/L (500/mm\^3) for 3 consecutive laboratory values obtained on different days. Date of ANC recovery is the date of the first of 3 consecutive laboratory values where the ANC is ≥ 0.5 × 109/L (CIBMTR). The first date of the 3 consecutive laboratory values obtained on different days where the platelet count was ≥ 20 × 109/L should be recorded. It should be ensured that no platelet transfusions were administered for 7 days immediately preceding this date (CIBMTR). |
| Relapse-free survival (RFS) | Up to 15 years | RFS is measured by the time from date of first documented disease response as CR or CRi to relapse or death due to any cause in ALL patients. In case a patient does not have relapse or death due to any cause prior to data cutoff, RFS will be censored at the date of the last adequate assessment on or prior to the earliest censoring event. |
| Event-free survival (EFS) for ALL patients | Up to 15 years | EFS is the time from date of first tisagenlecleucel infusion to treatment failure, relapse or death from any cause, whichever occurred first, for B-cell ALL patients. |
| Progression free survival (PFS) for DLBCL patients | Up to 15 years | PFS is defined as the time from the date of first infusion to the date of event defined as the first documented progression of lymphoma or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of the last adequate assessment. In case a patient does not have progression or death prior to data cutoff, PFS will be censored at the date of the last adequate assessment on or prior to the earliest censoring event. |
| Overall survival (OS) | Up to 15 years | Overall survival is the time from date of first tisagenlecleucel infusion to the date of death due to any reason, In case a patient is alive at the date of last contact on or before data cutoff, OS is censored at the date of last contact. |
| Overall response rate (ORR) | Up to 15 years | The overall response rate will be defined as the total proportion of participants exhibiting either the best overall response (BOR) of complete or partial responses and the proportion of patient with BOR of CR/PR or CR/CRi for ALL patients will be reported along with its 95% CI. For ALL participants, the BOR will be defined as a CR or a CRi in accordance with National Comprehensive Cancer Network (NCCN) guidelines and previous guidelines (Appelbaum et al 2007)(Cheson et al 2003). For lymphomas, the BOR will be defined as a CR or PR in accordance with the Cheson response criteria (Cheson et al 2007) and the Lugano classification (Cheson et al 2016). |
| MRD negative overall response rate | Up to 15 years | The percentage of B-cell ALL patients who achieve a Best Overall Response (BOR) of CR or CRi with a Minimal residual disease (MRD) negative bone marrow will be provided with 95% CI. |
| Duration of overall response (DOR) | Up to 15 years | Duration of overall response (DOR) applies only to patients whose best overall disease response was either: * CR or PR for patients with lymphomas, or * CR or a CRi for patients with ALL. DOR will be defined as the time from the date of first documented disease response (Complete Response (CR) or PR for patients with lymphomas, and Complete Remission (CR) or CRi for patients with ALL), whichever occurs first, to the date of first documented progression or first documented relapse according to indication, or to the date of death due to the underlying disease. In case a patient does not have progression/relapse or death due to underlying disease (defined as the event for this outcome) prior to data cut-off, DOR will be censored at the date of the last assessment on or prior to the earliest censoring event. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and severity of CRS and ICANS among HTLV 1 and 2 positive versus HTLV 1 and 2 negative patients | Up to 15 years | Incidence and severity of Cytokine release syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) among Human T-cell Lymphotropic Virus (HTLV) 1 and 2 positive versus HTLV 1 and 2 negative patients. For CRS AE the protocol will follow the American Society of Transplant and Cellular Therapy (ASTCT) CRS Consensus Grading. For ICANS AE the protocol will follow ASTCT consensus as well. Which establishes the Immune effector Cell-associated Encephalopathy (ICE Score) for adults/ adolescents and Cornell Assessment of Pediatric Delirium (CAPD) for pediatric patients under 12 years |
| Pregnancy rates | Up to 15 years | Pregnancy rates will be collected |
| Number of patients with confirmed secondary malignancies diagnosis | Up to 15 years | Number of patients with confirmed secondary malignancies diagnosis will be collected |
| The type and frequency of SAEs and AE of special interest | Up to 15 years | The type and frequency of SAEs and AE of special interest (including secondary malignancies) will be collected |
Countries
Brazil
Contacts
Primary ContactNovartis Pharmaceuticals
Backup ContactNovartis Pharmaceuticals
Outcome results
None listed